
Product Data Sheet

Product Name: INY-03-041 trihydrochloride

Cat. No.: GC67757

Chemical Properties

Cas. No.

Formula C₄₄H₅₉Cl₄N₇O₅

M.Wt

907.8

Solubility

Storage

Store at -20°C

General tips

For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-**Akt** degrader consisting of the ATP-competitive **Akt** inhibitor Ipatasertib conjugated to Lenalidomide . INY-03-041 trihydrochloride inhibits **AKT1**, **AKT2** and **AKT3** with **IC₅₀**s of 2.0, 6.8 and 3.5 nM, respectively^[1].

INY-03-041 (10-1000 nM; 0-24 hours) induces potent degradation of all three AKT isoforms in MDA-MB-468 cells^[1].

INY-03-041 exhibits potent in vitro inhibition of S6K1 (IC₅₀ =37.3 nM) and PKG1 (IC₅₀ = 33.2 nM)^[1].

INY-03-041 displays enhanced anti-proliferative effects compared with Ipatasertib in MDA-MB-468 and HCC1937 cells^[1].

INY-03-041 (250 nM, 12 h) promotes sustained AKT degradation and inhibition of downstream signaling effects for up to 96 h, even after compound washout^[1].

Western Blot Analysis^[1]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cell Line: MDA-MB-468 cells

Concentration: 0, 10, 50, 100, 250, 500, and 1000 nM

Incubation Time: 0, 2, 4, 6, 8, 10, 12, and 24 h

Result: Induced potent degradation of all three AKT isoforms in a dose-dependent manner after a 12-h treatment, with maximal degradation observed between 100 and 250 nM. At concentrations of 500 nM and greater, AKT degradation is diminished. Treatment with 250 nM of INY-03-041 over time reveals partial degradation of all AKT isoforms within 4 h and progressive loss of AKT abundance out to 24 h.

[1]. You I, et al. Discovery of an AKT Degradator with Prolonged Inhibition of Downstream Signaling. *Cell Chem Biol.* 2020 Jan 16;27(1):66-73.e7.

[2]. Maira SM, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. *Mol Cancer Ther.* 2012 Feb;11(2):317-28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA